Biotechnology and precision medicine company Caris Life Sciences announced it raised $168 million in growth capital funding. Caris Life Sciences has now raised $1.86 billion in capital since 2018.

Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial public offering, aiming to raise up to $423.5 million.

(Reuters) -Caris Life Sciences' shares jumped nearly 29% in their Nasdaq debut on Wednesday, fetching the cancer diagnostic firm a valuation of $7.66 billion and signaling a growing investor ...

Caris Life Sciences Inc., a health-care company that uses technology to help diagnose and treat cancer, raised $494 million in a US initial public offering that priced above the top of its ...

The Pistons, meanwhile, are strongly expected to focus on signing Caris LeVert away from the Hawks while Sacramento — as we've been reporting for days — is widely expected to come to terms ...

Irving, Texas-based Caris, backed by investment firm Sixth Street, is seeking up to $423.5 million by offering 23.5 million shares priced between $16 and $18 apiece.